To main content (press Enter)

Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Gosselies

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, announced the completion and opening of a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies, in Gosselies.

The new state-of-the-art facility will be one of the largest in the world, with 5,600 square meters of dedicated cell therapy manufacturing space housing multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing through to late-stage clinical and commercial-scale supply. The facility has been designed to be EMEA and FDA compliant, with Grade B and C suites to support high-throughput processes and accommodate bioreactor-scale cell therapy manufacturing as well as on-site quality control (QC) laboratories and warehousing.

The newly completed facility is the latest addition to Catalent’s Gosselies campus, which already includes a 6,200-square-meter clinical manufacturing facility offering customers advanced clinical and commercial supply solutions. The overall Gosselies campus provides a one-stop shop, with process and analytical development labs, more than 20 CGMP grade B and C cleanrooms, dedicated QC labs, qualified person (QP) services, and warehousing.

“Catalent enables fully integrated cell therapy services - from our iPSC expertise in Düsseldorf, Germany, to process and analytical development in Gosselies, to clinical and commercial manufacturing in Gosselies and Princeton, New Jersey - all under one CGMP umbrella,” said Manja Boerman, Catalent’s President, BioModalities (Cell, Gene and Protein Therapies). “Together with our integrated plasmid DNA and viral vector services, the Catalent Cell & Gene Therapy network provides end-to-end services for development, scale up, and commercial launch of advanced therapies.”

The Gosselies campus also includes separate plasmid DNA (pDNA) development and manufacturing facilities. The clinical-scale pDNA facility, at 1,600 square meters, includes R&D, process development, QC labs, and multiple CGMP production suites. The commercial-scale pDNA facility, at 3,010 square meters, offers large-scale manufacturing.

Also interesting

Aptaskil 3

aptaskil Competence Centre expands and goes digital to better meet talent needs in chemistry, biopharma and biotech

aptaskil, the competence centre for the chemical, biopharmaceutical, and biotechnological professions in Seneffe, is entering a new era with new infrastructure, larger training capacity and a major shift to digitalization of teaching methods. Over 8 million euros have been invested to upgrade the initial infrastructure, adding 1,400 m² of training facilities including clean rooms and laboratories, allowing the centre to train up to 6,000 learners each year (job seekers, workers, students), using, among other things, the latest virtual reality applications. The official opening was attended by Willy Borsus, Vice-President of Wallonia and Minister for Competence Centres.

Read more
Gsk and imec hero

GSK and imec to collaborate on disruptive innovation in pharma

A collaboration between GSK, a multinational pharma company whose vaccines headquarters are in Wallonia, and imec, a leading nanoelectronics research centre based in Flanders, is bringing together in Belgium two of its most innovative sectors...

Read more

EU Biotech Campus: construction works have begun to build and develop the biotech sector and talents of the future in Wallonia

This state-of-the-art training centre with business accelerator – supported by essenscia – has an ambitious mission. Train more talent and support more start-ups and scale-ups to further strengthen the leading international position of the Belgian and Walloon biotech and biopharmaceutical sector.

Read more

Interested in updates on our
insights, news and testimonials?